Vaxcyte, Inc. (PCVX)
63.89
+1.97
(+3.18%)
USD |
NASDAQ |
Nov 06, 16:00
63.88
0.00 (0.00%)
After-Hours: 20:00
Vaxcyte Research and Development Expense (Quarterly) : 270.33M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 270.33M |
| June 30, 2026 | 267.85M |
| March 31, 2026 | 312.78M |
| December 31, 2025 | 242.06M |
| September 30, 2025 | 209.93M |
| June 30, 2025 | 194.18M |
| March 31, 2025 | 148.13M |
| December 31, 2024 | 133.61M |
| September 30, 2024 | 116.94M |
| June 30, 2024 | 131.51M |
| March 31, 2024 | 94.59M |
| December 31, 2023 | 104.15M |
| September 30, 2023 | 97.42M |
| June 30, 2023 | 72.69M |
| March 31, 2023 | 58.08M |
| December 31, 2022 | 51.63M |
| Date | Value |
|---|---|
| September 30, 2022 | 47.68M |
| June 30, 2022 | 38.47M |
| March 31, 2022 | 31.68M |
| December 31, 2021 | 23.07M |
| September 30, 2021 | 20.43M |
| June 30, 2021 | 17.65M |
| March 31, 2021 | 17.26M |
| December 31, 2020 | 14.66M |
| September 30, 2020 | 16.41M |
| June 30, 2020 | 18.18M |
| March 31, 2020 | 24.32M |
| December 31, 2019 | 13.38M |
| September 30, 2019 | 9.63M |
| June 30, 2019 | 9.968M |
| March 31, 2019 | 12.63M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Moderna, Inc. | 515.00M |
| Vir Biotechnology, Inc. | 78.63M |
| Anavex Life Sciences Corp. | -4.705M |
| Revolution Medicines, Inc. | 412.00M |
| Foghorn Therapeutics, Inc. | 18.32M |